FDA Grants Regular Approval to Pembrolizumab/Lenvatinib Combination for Endometrial Carcinoma

The FDA has granted regular approval to pembrolizumab (Keytruda®, Merck), in combination with lenvatinib, (Lenvima®, Eisai), for patients with advanced endometrial carcinoma that is not microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. Prior to this regular approval, the FDA granted accelerated approval to the pembrolizumab/lenvatinib co...
Continue reading

Lenvatinib Plus Pembrolizumab Approved for Advanced Endometrial Carcinoma

The FDA has approved lenvatinib (Lenvima®, Eisai) plus pembrolizumab (Keytruda®, Merck) for patients with advanced endometrial carcinoma who experience disease progression after at least one prior systemic therapy but are ineligible for curative surgery or radiation. Lenvatinib/pembrolizumab is indicated for patients whose cancer is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). "Lenvatinib is a multikinase inhibitor of VEGFR1, VEGFR2, and VEGFR3, and other rece...
Continue reading

In Endometrial Cancer, Chemoradiotherapy Improves Outcomes

​Adjuvant chemoradiotherapy increases five-year overall survival and failure-free survival compared with radiotherapy alone for women with high-risk endometrial cancer, report the researchers of the phase 3 PORTEC-3 trial in their updated analysis, which has now been published in The Lancet Oncology. Around 15% to 20% of patients with endometrial cancer are considered to have high-risk endometrial cancer, defined as endometrioid endometrial cancer stage 1, grade 3 with deep invasion; stage II or...
Continue reading

Endometrial Cancer: Chemoradiotherapy Versus Chemo Alone

​Because endometrial carcinoma is a heterogeneous disease, it is often difficult to treat, and women diagnosed with advanced disease are at risk for local and systemic recurrence. When researchers tested platinum-based chemotherapy plus radiation therapy against chemotherapy alone in patients with stage III or IVA endometrial carcinoma to see which treatment improved outcomes the most, they discovered that chemoradiotherapy did not improve outcomes more so than chemotherapy alone. This study, re...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.